Centogene N.V. (Nasdaq: CNTG), the essential life science
partner for data-driven answers in rare and neurodegenerative
diseases, today revealed significant growth in the CENTOGENE
Biodatabank, the world’s largest real-world data repository for
rare and neurodegenerative diseases. Analysis of this patient data
enables precise diagnosis of disease, identification of new genetic
variants, and potential de-risking of drug development.
The number of analyzed patient cases has grown by 13% to more
than 850,000 patients as of December 31, 2023, compared to December
21, 2022, and the number of total unique variants has increased by
19% to over 850,000,000. This includes patients from over 120
countries, over 70% of whom are of non-European descent,
underscoring the ethnic diversity of CENTOGENE’s knowledgebase.
“Our comprehensive genomic and multiomic analyses are key to
fostering the richest data within the CENTOGENE Biodatabank. This
not only fuels the further innovation of our diagnostic portfolio,
but supports our pharmaceutical partners in fast-tracking the
discovery, development, and commercialization of orphan drugs,”
said Kim Stratton, Chief Executive Officer at CENTOGENE.
“Ultimately, our commitment is to deliver data-driven,
life-changing answers to rare and neurodegenerative disease
patients around the world, and the CENTOGENE Biodatabank is the
cornerstone of this mission.”
Enabling Diagnostic Excellence
The CENTOGENE Biodatabank has enabled CENTOGENE to work
alongside its active physician network of approximately 30,000
physicians to diagnose over 2,500 rare and neurodegenerative
diseases across 120 countries. With the CENTOGENE Biodatabank
serving as the backbone, the Company has the broadest diagnostic
testing portfolio for rare diseases, covering over 19,000 genes
using approximately 5,000 different tests. As of December 31, 2023,
over 570,000 CentoCards®, CENTOGENE’s proprietary sample collection
solution, and archived samples are stored in the Company’s
physical biobank, which enables retrospective analysis for research
consented samples.
Driving Disease Understanding
Since 2006, CENTOGENE has generated data-driven insights from
its Diagnostics segment. Leveraging these insights via in-house
research, the Company has discovered unique links between rare and
neurodegenerative diseases, like Parkinson’s disease and
frontotemporal dementia. CENTOGENE’s R&D team has contributed
to top tier studies, recently hitting a milestone of 300
peer-reviewed publications. As a result, patients affected by
thousands of rare and neurodegenerative diseases have been
diagnosed and gained access to available treatment options, while
opening the potential to diagnose and treat countless others based
on this research.
Accelerating Treatment Options
Leveraging the CENTOGENE Biodatabank at the core of the
Company’s business, CENTOGENE had a total of 48 collaborations with
34 different pharmaceutical partners during 2023 – working together
to accelerate diagnoses and de-risk drug discovery, development,
and commercialization. Of these 48 collaborations, 12 were with new
partners, including the Michael J. Fox Foundation and Chiesi, among
others. Starting off Q1 2024, the Company has extended its
relationships with existing biopharma partners, such as Takeda with
their Lysosomal Storage Disorders (LSDs) diagnostic testing
program, as well as formed collaborations with eight new partners,
such as Alexion, AstraZeneca Rare Disease.
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
850,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 300 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “potential,” “predict,” “objective” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth, execute our
business strategy and enter into new client relationships, our
dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our continued ongoing compliance with
covenants linked to financial instruments, our requirement for
additional financing, and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on May 16, 2023,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
CONTACT
CENTOGENE
Melissa HallCorporate Communications Press@centogene.com
Lennart StreibelInvestor Relations IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Centogene NV (NASDAQ:CNTG)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
